Trade Champions Oncology, Inc. - CSBR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.18 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 9.83 |
| Open | 9.99 |
| 1-Year Change | 48% |
| Day's Range | 9.64 - 9.99 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 9.76 | -0.23 | -2.30% | 9.99 | 9.99 | 9.57 |
| Jan 16, 2025 | 9.83 | 0.64 | 6.96% | 9.19 | 9.94 | 9.18 |
| Jan 15, 2025 | 9.23 | -0.09 | -0.97% | 9.32 | 9.70 | 8.88 |
| Jan 14, 2025 | 9.45 | 0.45 | 5.00% | 9.00 | 9.58 | 8.88 |
| Jan 13, 2025 | 9.07 | -0.35 | -3.72% | 9.42 | 9.68 | 8.85 |
| Jan 10, 2025 | 9.45 | -0.16 | -1.66% | 9.61 | 9.80 | 9.01 |
| Jan 8, 2025 | 9.65 | -0.33 | -3.31% | 9.98 | 9.99 | 9.24 |
| Jan 7, 2025 | 10.27 | 0.75 | 7.88% | 9.52 | 10.76 | 9.24 |
| Jan 6, 2025 | 9.40 | 0.10 | 1.08% | 9.30 | 9.48 | 8.90 |
| Jan 3, 2025 | 9.62 | 1.71 | 21.62% | 7.91 | 9.64 | 7.91 |
| Jan 2, 2025 | 8.19 | -0.32 | -3.76% | 8.51 | 8.51 | 7.75 |
| Dec 31, 2024 | 8.42 | -0.12 | -1.41% | 8.54 | 8.68 | 8.19 |
| Dec 30, 2024 | 8.61 | 0.60 | 7.49% | 8.01 | 9.22 | 8.01 |
| Dec 27, 2024 | 8.26 | 0.21 | 2.61% | 8.05 | 8.33 | 7.53 |
| Dec 26, 2024 | 8.06 | 0.37 | 4.81% | 7.69 | 8.33 | 7.51 |
| Dec 24, 2024 | 7.85 | -0.16 | -2.00% | 8.01 | 8.27 | 7.78 |
| Dec 23, 2024 | 8.17 | 1.65 | 25.31% | 6.52 | 8.84 | 6.52 |
| Dec 20, 2024 | 7.47 | 0.13 | 1.77% | 7.34 | 7.54 | 6.92 |
| Dec 19, 2024 | 7.44 | 0.45 | 6.44% | 6.99 | 7.81 | 6.71 |
| Dec 18, 2024 | 6.81 | 0.38 | 5.91% | 6.43 | 7.18 | 6.38 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Champions Oncology, Inc. Company profile
About Champions Oncology Inc
Champions Oncology, Inc. is engaged in creating transformative technology solutions to be utilized in oncology drug discovery and development. This technology includes the Company’s in-vivo, ex-vivo and biomarker platforms, oncology software solutions, and computational-based discovery platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology. The Company’s software as a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. The Company’s drug discovery and development business leverages the computational and experimental capabilities within its platforms. Their discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify novel therapeutic targets.
Financial summary
BRIEF: For the nine months ended 31 January 2022, Champions Oncology Inc revenues increased 19% to $36.2M. Net income decreased 14% to $892K. Revenues reflect Pharmacology services segment increase of 66% to $34.5M, Other segment increase from $101K to $1.7M. Net income was offset by research and development increase of 32% to $6.8M (expense), general and administratiojn increase of 32% to $5.9M (expense).
Equity composition
Common Stock $.001 Par, 01/11, 50M auth., 36,853,000 issd. less 1,236,000 shs. in Treas. @ $292K. Insiders & strategic holders own 64.79%. Public Offering 9/85, 40M Units (1 sh. com. + 3 warrants) @ $.01 by the Company. 02/07, Name changedfrom Champions Sports Inc.08/15, 1-for-12 Reverse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
Suite 619
855 N. Wolfe Street
BALTIMORE
MARYLAND 21205
US
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com